Coya Therapeutics News

Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital

Coya Therapeutics Price Target Maintained With a $14.00/Share by Chardan Capital

Dow JonesApr 29 20:16

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Serum 4-HNE levels are increased in bulbar vs. limb onset ALS patients and correlate with shortened survival in patients with bulbar onset ALS;

Business WireApr 26 20:15

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer

BusinesswireApr 22 20:15

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief

BusinesswireApr 18 20:15

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April 26, 2024. The title of the poster is 4-hydroxynonenal (4-HNE) as a Biomarker in ALS.

BusinesswireApr 8 20:15

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate

Yahoo FinanceMar 27 20:37

Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates

Yahoo FinanceMar 21 17:31

Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Coya Therapeutics, Inc. (COYA) and Iovance Biotherapeutics (IOVA)

TipRanksMar 20 18:01

Coya Therapeutics Is Maintained at Buy by Chardan Capital

Coya Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 20 17:41

Chardan Capital Maintains Buy on Coya Therapeutics, Raises Price Target to $14

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics with a Buy and raises the price target from $11 to $14.

Analyst UpgradesMar 20 17:31

Coya Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 31.09% Chardan Capital $11 → $14 Maintains Buy 08/09/2023 162.17% EF Hutton → $28 Reiterates Bu

BenzingaMar 20 17:29

Strengthened Financials and Promising Pipeline Position Coya Therapeutics for Success

TipRanksMar 20 14:25

Coya Therapeutics GAAP EPS of -$0.79

Seeking AlphaMar 19 22:21

Coya Therapeutics Financial Update and Performance Review

TipRanksMar 19 20:32

Coya Therapeutics FY23 EPS $(0.79) Vs $(4.73) YoY; Collaboration Revenue Of 6M

Financial ResultsAs of December 31, 2023, Coya had cash and cash equivalents of $32.6 million and received an additional $7.5 million in January from Dr. Reddy's as an upfront payment as part of the C

BenzingaMar 19 20:19

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results HOUSTON--(BUSINESS WIRE)--March 19, 2024-- Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a

Dow JonesMar 19 20:15

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Stockhouse Mar 19 20:15

Coya Therapeutics to Participate in BTIG Fireside Discussion

Coya's Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the

BusinesswireMar 12 21:00

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

4-Hydroxynonenal (4-HNE) levels strongly correlate with rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and survival of patients from onset and diagnosis to death (91.7% sensitivity an

BusinesswireMar 12 20:00

Buy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment Approach

TipRanksMar 11 05:26